Bristol-Myers Squibb Compnay

Bristol-Myers Squibb Pharma Company

Other

Patrick Y S Lam

Charles G Clark

Donald J P Pinto

Jennifer X Qiao

Yun-Long Li

Mimi Lifen Quan

Michael J Orwat

Carl Thibeault

Alexandre L'Heureux

Wu Yang

Yufeng Wang

Tammy C Wang

Rejean Ruel

Stephanie L Koch

Renhau Li

Ruth Richmond Wexler

Yoon T Jeon

Irina C Jacobson

Zulan Pi

Wei Han

Timur Gungor

William R Ewing

James R Corte

Paul Joseph Gilligan

Leon M Smith, Ii

John Matthew Fevig

James Clifford Sutton

Jacques Y Roberge

Robert A Galemmo, Jr

Qi Han

Carol Hui Hu

Timothy F Herpin

Hannguang J Chao

Robert P Rehfuss

Gilles Bouthillier

Huji Tuerdi

Dora M Schnur

Yalei Liu

R Michael Lawrence

John E Lloyd

George O Tora

Donald J Pinto

Michael S Bowsher

Carl Thibault

Sheldon Hiebert

Michael R Lawrence

Indawati DeLucca

Ruel Rejean

The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Yreceptor which may be used medicaments. 

[object Object]

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Yreceptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders. 

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Cyclic P1 linkers as factor XIa inhibitors

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. 

The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

The present invention provides indole compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables ring A, X, X, X, X, R, and Rare as defined herein. These compounds are selective inhibitors of the human P2Yreceptor which can be used as medicaments.

The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

The present application describes lactam-containing compounds and derivatives thereof of Formula I:P-P-M-MIor pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Lactam-containing compounds and derivatives thereof as factor Xa inhibitors

The present application describes sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds and derivatives thereof of Formula I:P-P-M-MIor pharmaceutically acceptable salt forms thereof, wherein M is a ring, P is an optional ring, and Pand Mare as defined below. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors

The present application describes lactam-containing compounds and derivatives thereof of Formula I:PIor pharmaceutically acceptable salt forms thereof, wherein

The present application describes lactam-containing compounds and derivatives thereof of Formula I: P-P-M-M I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5&#x2013;7 membered carbocycle or heterocycle and ring M is a 5&#x2013;7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

The present application describes lactam-containing compounds and derivatives thereof of Formula I:P&#x2014;P-M-M&#x2003;&#x2003;Ior pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

The present application describes lactam-containing compounds and derivatives thereof of Formula I:or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Growing community of inventors

Chadds Ford, PA, United States of America

Patrick Y S Lam